SCYNEXIS Completes Phase 1 Study Of SCY-770, Selective And Direct AMP-Activated Protein Kinase Activator

SCYNEXIS, Inc. has completed a Phase 1 study of SCY-770, a selective and direct AMP-activated protein kinase activator, which demonstrated a favorable safety profile in healthy adult participants. The company plans to initiate a Phase 2 proof-of-concept study in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the fourth quarter of 2026. SCY-770 aims to address multiple drivers of cyst growth and disease progression in ADPKD.